Oral Ethinyl Estradiol, but not Transdermal 17β-estradiol, Increases Plasma C-reactive Protein Levels in Men

Erik J. Giltay; Louis J. G. Gooren; Jef J. Emeis; Teake Kooistra; Coen D. A. Stehouwer

doi:10.1055/s-0037-1614026

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 84(02): 359-360
DOI: 10.1055/s-0037-1614026

Letters to the Editor

Schattauer GmbH

Oral Ethinyl Estradiol, but not Transdermal 17β-estradiol, Increases Plasma C-reactive Protein Levels in Men

Erik J. Giltay

¹From the Research Institute for Endocrinology, Reproduction and Metabolism, the Netherlands

,

Louis J. G. Gooren

¹From the Research Institute for Endocrinology, Reproduction and Metabolism, the Netherlands

,

Jef J. Emeis

²The Gaubius Laboratory, TNO-PG, Leiden, the Netherlands

,

Teake Kooistra

²The Gaubius Laboratory, TNO-PG, Leiden, the Netherlands

,

Coen D. A. Stehouwer

³The Department of Internal Medicine, University Hospital Vrije Universiteit, Amsterdam, the Netherlands

› Author Affiliations

Abstract

Full Text

References

References
1 Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987; 65: 1-11.
2 Liuzzo G, Biasucci LM, Gallimore JR, Grille RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
3 Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van De Loo JCW. for the European Concerted Action on Thrombosis and disabilities angina pectoris study. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
4 Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
5 Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effects of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999; 100: 717-22.
6 Van Baal WM, Kenemans P, Van Der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-8.
7 Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu IK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-20.
8 Giltay EJ, Gooren LJG, Emeis J, Kooistra T, Stehouwer CDA. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels without affecting its endothelial synthesis. Arterioscler Thromb Vase Biol 2000; 20: 1396-403.
9 Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
10 Sattar N, Perera M, Small M, Lumsden MA. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 1999; 354: 487-8.